Skip to content
Catalyst

theophyllineWhat was measured

Measured, with no finding

243 endpoints

Show what was measuredHide what was measured
  • breathlessness

    no effect

    neither did Visual Analogue Score for breathlessness isn two small studies (WMD 3.6, 95%CI -4.6, 11.8)

    PMID 12519617 · one of two readings recorded this

  • FEV1, pooled weighted mean difference, oral theophylline versus placebo in stable COPD (also FVC, VO2max, PaO2, PaCO2, walking distance, breathlessness VAS)

    increases, WMD 100 ml; 95% CI 40, 160 ml

    Not recorded as a finding: the supporting sentence never names the compound

    FEV1 improved with treatment: Weighted Mean Difference (WMD) 100 ml; 95% Confidence Interval (95%CI) 40, 160 ml.

    PMID 12519617 · one of two readings recorded this

  • FEV1, weighted mean difference versus placebo, oral theophylline in stable COPD

    increases, WMD 100 ml (95% CI 40, 160 ml)

    Not recorded as a finding: the supporting sentence never names the compound

    FEV1 improved with treatment: Weighted Mean Difference (WMD) 100 ml; 95% Confidence Interval (95%CI) 40, 160 ml.

    PMID 12519617 · one of two readings recorded this

  • FEV1

    increases

    FEV1 improved with treatment: Weighted Mean Difference (WMD) 100 ml; 95% Confidence Interval (95%CI) 40, 160 ml

    PMID 12519617 · one of two readings recorded this

  • FVC

    increases

    Similarly for FVC: WMD 210 ml 95%CI 100, 320

    PMID 12519617 · one of two readings recorded this

  • nausea

    increases

    The Relative Risk (RR) of nausea was greater with theophylline (RR 7.7; 95%CI 1.5, 39.9)

    PMID 12519617 · one of two readings recorded this

  • PaCO2 at rest

    decreases

    At rest, PaO2 and PaCO2 both improved with treatment (WMD 3.2 mmHg; 95%CI = 1.2, 5., and WMD -2.4 mmHg; 95%CI = -3.5, -1.2, respectively)

    PMID 12519617 · one of two readings recorded this

  • PaO2 at rest

    increases

    At rest, PaO2 and PaCO2 both improved with treatment (WMD 3.2 mmHg; 95%CI = 1.2, 5., and WMD -2.4 mmHg; 95%CI = -3.5, -1.2, respectively)

    PMID 12519617 · one of two readings recorded this

  • patient preference

    increases

    However, patients' preference for theophylline was greater than that for placebo (RR 2.27; 95%CI = 1.26, 4.11)

    PMID 12519617 · one of two readings recorded this

  • VO2max

    increases

    Two studies reported an improvement in VO2max; WMD 195 ml/min, 95%CI 113,27

    PMID 12519617 · one of two readings recorded this

  • walking distance tests

    no effect

    Walking distance tests did not improve (4 studies, Standardised Mean Difference 0.30, 95%CI -0.01, 0.62)

    PMID 12519617 · one of two readings recorded this

  • adverse events (any)

    decreases

    Participants taking salmeterol experienced fewer adverse events than those using theophylline (Parallel studies: Relative Risk 0.44; 95% CI 0.30 to 0.63, Risk Difference -0.11; 95% CI -0.16 to -0.07, Numbers Needed to Treat (NNT) 9; 95% CI 6 to 14)

    PMID 17636663 · one of two readings recorded this

  • central nervous system adverse events

    decreases

    Significant reductions were reported for central nervous system adverse events (Relative Risk 0.50; 95% CI 0.29 to 0.86, Risk Difference -0.07; 95% CI -0.12 to -0.02, NNT 14; 95% CI 8 to 50)

    PMID 17636663 · one of two readings recorded this

  • efficacy (bitolterol versus theophylline)

    decreases

    Bitolterol, used in only one study, was reported to be less effective than theophylline

    PMID 17636663 · one of two readings recorded this

  • efficacy (formoterol versus theophylline)

    no effect

    Formoterol, used in two studies was reported to be as effective as theophylline

    PMID 17636663 · one of two readings recorded this

  • evening PEF

    increases

    evening PEF (mean difference 15.58 L/min, 95% CI 8.33 to 22.83)

    PMID 17636663 · one of two readings recorded this

  • FEV(1) predicted

    no effect

    There was no significant difference between salmeterol and theophylline in FEV(1) predicted (6.5%; 95% CI -0.84 to 13.83)

    PMID 17636663 · one of two readings recorded this

  • FEV1 percent predicted, salmeterol versus oral sustained-release theophylline

    no effect, 6.5% (95% CI -0.84 to 13.83)

    Not recorded as a finding: the comparison was against another active treatment

    There was no significant difference between salmeterol and theophylline in FEV(1) predicted (6.5%; 95% CI -0.84 to 13.83).

    PMID 17636663 · one of two readings recorded this

  • FEV1 % predicted, pooled mean difference, salmeterol versus theophylline in asthma (also morning and evening PEF, rescue medication use, adverse events)

    no effect, 6.5%; 95% CI -0.84 to 13.83 (salmeterol versus theophylline)

    Not recorded as a finding: the comparison was against another active treatment

    There was no significant difference between salmeterol and theophylline in FEV(1) predicted (6.5%; 95% CI -0.84 to 13.83).

    PMID 17636663 · one of two readings recorded this

  • gastrointestinal adverse events

    decreases

    and gastrointestinal adverse events (Relative Risk 0.30; 95% CI 0.17 to 0.55, Risk Difference -0.11; 95% CI -0.16 to -0.06, NNT 9; 95% CI 6 to 16)

    PMID 17636663 · one of two readings recorded this

  • morning PEF

    increases

    salmeterol treatment led to significantly better morning PEF (mean difference 16.71 L/min, 95% CI 8.91 to 24.51)

    PMID 17636663 · one of two readings recorded this

  • short-acting beta-2 agonist requirement, daytime

    decreases

    There is evidence of decreased daytime and nighttime short-acting beta-2 agonist requirement with salmeterol

    PMID 17636663 · one of two readings recorded this

  • short-acting beta-2 agonist requirement, nighttime

    decreases

    There is evidence of decreased daytime and nighttime short-acting beta-2 agonist requirement with salmeterol

    PMID 17636663 · one of two readings recorded this

  • use of rescue medication

    decreases

    Salmeterol also reduced the use of rescue medication

    PMID 17636663 · one of two readings recorded this

  • peak FEV1

    increases, n = 800

    Twelve studies with 800 patients combined contributed data for the analysis of peak FEV1, which showed a significant improvement of 96 mL over placebo (WMD 0.096 L; 95% CI=0.04–0.15)

    PMID 18046863 · one of two readings recorded this

  • peak FEV1

    increases, n = 400

    For trough and peak FEV1, the largest contribution of data (400 patients) was derived from a single study that showed a significant improvement over placebo of 90 mL and 80 mL, respectively

    PMID 18046863 · one of two readings recorded this

  • peak FVC

    increases, n = 358

    Ten studies with 358 patients combined contributed data for the analysis of peak FVC, which showed a significant improvement of 242 mL over placebo (WMD 0.242 L; 95% CI=0.11–0.37)

    PMID 18046863 · one of two readings recorded this

  • peak (post-dose) FEV1, pooled weighted mean difference versus placebo

    increases, WMD 0.096 L (95% CI 0.04-0.15), n = 800

    Not recorded as a finding: The only sentence never names theophylline (it says 'over placebo' only), so it is not self-supporting on its own.

    Twelve studies with 800 patients combined contributed data for the analysis of peak FEV1, which showed a significant improvement of 96 mL over placebo (WMD 0.096 L; 95% CI=0.04–0.15).

    PMID 18046863 · one of two readings recorded this

  • peak (post-dose) FEV1, pooled WMD, oral theophylline versus placebo

    increases, n = 800

    Not recorded as a finding: the only sentence reporting it never names theophylline (it reads 'improvement of 96 mL over placebo'), so it is not self-supporting on its own

    Twelve studies with 800 patients combined contributed data for the analysis of peak FEV1, which showed a significant improvement of 96 mL over placebo (WMD 0.096 L; 95% CI=0.04–0.15).

    PMID 18046863 · one of two readings recorded this

  • peak (post-dose) forced vital capacity (FVC), pooled WMD, spirometry

    increases, n = 358

    Not recorded as a finding: no outcome node for forced vital capacity

    Ten studies with 358 patients combined contributed data for the analysis of peak FVC, which showed a significant improvement of 242 mL over placebo (WMD 0.242 L; 95% CI=0.11–0.37).

    PMID 18046863 · one of two readings recorded this

  • trough FEV1

    increases, n = 704

    Ten studies with 704 patients combined contributed data for the analysis of trough FEV1, which showed a significant improvement for theophylline of 108 mL over placebo (WMD 0.108 L; 95% CI=0.05–0.16)

    PMID 18046863 · one of two readings recorded this

  • trough FEV1

    increases, n = 400

    For trough and peak FEV1, the largest contribution of data (400 patients) was derived from a single study that showed a significant improvement over placebo of 90 mL and 80 mL, respectively

    PMID 18046863 · one of two readings recorded this

  • trough forced vital capacity (FVC), pooled WMD, spirometry

    increases, n = 166

    Not recorded as a finding: no outcome node for forced vital capacity

    Six studies with 166 patients combined contributed data for the analysis of trough FVC, which showed a significant improvement of 186 mL over placebo (WMD 0.186 L; 95% CI=0.04–0.34).

    PMID 18046863 · one of two readings recorded this

  • trough FVC

    increases, n = 166

    Six studies with 166 patients combined contributed data for the analysis of trough FVC, which showed a significant improvement of 186 mL over placebo (WMD 0.186 L; 95% CI=0.04–0.34)

    PMID 18046863 · one of two readings recorded this

  • asthma exacerbation rate

    unclear

    eight patients (5.2%) with an increase in ICS dose and three patients (1.9%) with addition of theophylline reported exacerbations

    PMID 21319345 · one of two readings recorded this

  • asthma exacerbation rate

    no effect

    Two trials examined exacerbation rates due to asthma, and their results showed there were no statistical differences in exacerbation rates between the groups

    PMID 21319345 · one of two readings recorded this

  • evening peak expiratory flow (PEF)

    no effect, p = 0.2

    There was no difference between treatments in terms of morning (p = 0.77) or evening (p = 0.20) PEF

    PMID 21319345 · one of two readings recorded this

  • evening peak expiratory flow (PEF)

    increases

    the increases in PEF with addition of theophylline were higher, by 11.20 liter/min (95% CI 9.14-13.25) in the morning and by 9.85 liter/min (95% CI 7.55-12.14) in the evening, than with increasing the dose of ICS for the strata of six-week duration

    PMID 21319345 · one of two readings recorded this

  • evening peak expiratory flow (PEF)

    no effect

    For the strata of duration longer than six weeks, evening PEF showed no difference

    PMID 21319345 · one of two readings recorded this

  • FEV1 as % predicted (FEV1pred)

    increases, p = 0.00001

    Addition of theophylline produced a significantly greater increase by 2.49% [weighted means difference (WMD) = 2.49; 95% CI 1.99-3.00; z = 9.70; p < 0.00001] than increasing the dose of ICS in FEV1pred

    PMID 21319345 · one of two readings recorded this

  • FEV1 as % predicted (FEV1pred)

    increases

    The random effect duramodel of FEV1pred showed a pooled WMD of 2.51 (95% CI 1.82-3.20)

    PMID 21319345 · one of two readings recorded this

  • FEV1 as % predicted (spirometry), pooled weighted mean difference, adding theophylline to inhaled corticosteroid versus increasing the inhaled corticosteroid dose in symptomatic asthma (also home PEF, rescue medication, exacerbations)

    increases, WMD 2.49%; 95% CI 1.99-3.00

    Not recorded as a finding: the comparison was against another active treatment

    Addition of theophylline produced a significantly greater increase by 2.49% [weighted means difference (WMD) = 2.49; 95% CI 1.99-3.00; z = 9.70; p < 0.00001] than increasing the dose of ICS in FEV1pred.

    PMID 21319345 · one of two readings recorded this

  • FEV1 percent predicted, adding theophylline to ICS versus increasing the ICS dose

    increases, WMD 2.49% (95% CI 1.99-3.00)

    Not recorded as a finding: the comparison was against another active treatment

    Addition of theophylline produced a significantly greater increase by 2.49% [weighted means difference (WMD) = 2.49; 95% CI 1.99-3.00; z = 9.70; p < 0.00001] than increasing the dose of ICS in FEV1pred.

    PMID 21319345 · one of two readings recorded this

  • morning peak expiratory flow (PEF)

    no effect, p = 0.77

    There was no difference between treatments in terms of morning (p = 0.77) or evening (p = 0.20) PEF

    PMID 21319345 · one of two readings recorded this

  • morning peak expiratory flow (PEF)

    increases

    the increase in morning PEF was in favor of increasing the dose of ICS by 7.61 liter/min (95% CI 3.72-11.50)

    PMID 21319345 · one of two readings recorded this

  • morning peak expiratory flow (PEF)

    increases

    the increases in PEF with addition of theophylline were higher, by 11.20 liter/min (95% CI 9.14-13.25) in the morning and by 9.85 liter/min (95% CI 7.55-12.14) in the evening, than with increasing the dose of ICS for the strata of six-week duration

    PMID 21319345 · one of two readings recorded this

  • need for rescue medication

    no effect

    All four trials revealed improvement of symptom scores and need for rescue medication in both groups, and there was no significant difference between the two treatments

    PMID 21319345 · one of two readings recorded this

  • plasma cortisol level

    decreases

    Evans, et al. reported that the reduction of plasma cortisol level was observed only in the group given an increased dose of ICS after 12-week treatment

    PMID 21319345 · one of two readings recorded this

  • plasma cortisol level

    no effect

    Wang, et al. found there was no significant reduction in plasma cortisol in both treatments

    PMID 21319345 · one of two readings recorded this

  • symptom scores

    no effect

    All four trials revealed improvement of symptom scores and need for rescue medication in both groups, and there was no significant difference between the two treatments

    PMID 21319345 · one of two readings recorded this

  • abdominal pain

    no effect

    There were no differences in abdominal pain, psychological side effects, headaches, seizures, or tremor

    PMID 29391776 · one of two readings recorded this

  • admission rate

    no effect

    In almost every case, there were no significant differences between theophylline and control

    PMID 29391776 · one of two readings recorded this

  • cardiovascular adverse events

    increases

    Compared with placebo, IV theophylline caused more nausea, vomiting, and cardiovascular adverse events (such as palpitations and arrhythmias)

    PMID 29391776 · one of two readings recorded this

  • cardiovascular adverse events

    no effect

    was not different from the active controls in terms of the frequency of psychological side effects, headaches, cardiovascular adverse events, tremor, CPK/CK elevation, or glucosuria/hyperglycemia

    PMID 29391776 · one of two readings recorded this

  • CPK/CK elevation

    no effect

    was not different from the active controls in terms of the frequency of psychological side effects, headaches, cardiovascular adverse events, tremor, CPK/CK elevation, or glucosuria/hyperglycemia

    PMID 29391776 · one of two readings recorded this

  • duration of hospital stay, intravenous theophylline versus pooled control (active comparators and placebo or no drug)

    decreases, 0.23 hours shorter (95% CI -0.37 to -0.08 hours), p = 0.002

    Not recorded as a finding: the comparison was against another active treatment

    The exception was the duration of hospital stay, with theophylline reducing the duration of stay by 0.23 hours (14 minutes) (95% CI: −0.37, −0.08 hours, p=0.002).

    PMID 29391776 · one of two readings recorded this

  • duration of hospital stay, pooled mean difference in hours, theophylline versus control

    decreases, -0.23 hours (95% CI -0.37, -0.08), p=0.002, p = 0.002

    Not recorded as a finding: the pooled control is a mixture of active comparators, placebo and no drug, so the contrast is not theophylline against its absence; no placebo-only estimate is stated

    The exception was the duration of hospital stay, with theophylline reducing the duration of stay by 0.23 hours (14 minutes) (95% CI: −0.37, −0.08 hours, p=0.002).

    PMID 29391776 · one of two readings recorded this

  • duration of hospital stay

    decreases, p = 0.002

    The exception was the duration of hospital stay, with theophylline reducing the duration of stay by 0.23 hours (14 minutes) (95% CI: −0.37, −0.08 hours, p=0.002)

    PMID 29391776 · one of two readings recorded this

  • FEV1 as percent of predicted

    no effect, p = 0.13

    Pooling of the six studies measuring FEV1 as a percent of predicted showed no difference between theophylline and control (MD =3.78 [95% CI: −1.08, 8.63], p=0.13, data not shown)

    PMID 29391776 · one of two readings recorded this

  • FEV1

    no effect, p = 0.07

    Intravenous (IV) theophylline was not significantly different from adrenaline (p=0.12), a leukotriene receptor antagonist (p=0.81), or placebo (p=0.07) in increasing FEV1

    PMID 29391776 · one of two readings recorded this

  • FEV1

    no effect, p = 0.12

    Intravenous (IV) theophylline was not significantly different from adrenaline (p=0.12), a leukotriene receptor antagonist (p=0.81), or placebo (p=0.07) in increasing FEV1

    PMID 29391776 · one of two readings recorded this

  • FEV1

    decreases, p = 0.001

    A pooled analysis of all active controls, however, also showed a small but significantly improved FEV1 in the control compared with theophylline (MD =−0.14L [95% CI: −0.25, −0.02], p=0.001; Figure 3B)

    PMID 29391776 · one of two readings recorded this

  • FEV1

    decreases, p = 0.002

    was significantly worse than beta-2 agonists (mean difference [MD] =−0.20 L [95% CI: −0.34, −0.07], p=0.002)

    PMID 29391776 · one of two readings recorded this

  • FEV1

    no effect, p = 0.81

    Intravenous (IV) theophylline was not significantly different from adrenaline (p=0.12), a leukotriene receptor antagonist (p=0.81), or placebo (p=0.07) in increasing FEV1

    PMID 29391776 · one of two readings recorded this

  • FEV1

    no effect

    where patients were given bronchodilators with or without steroids, there was no significant differences between theophylline and control

    PMID 29391776 · one of two readings recorded this

  • FEV1

    decreases, p = 0.00001

    In studies where the background medication was oxygen only or no additional medication other than the study drug, the control drugs performed better than theophylline (p<0.00001)

    PMID 29391776 · one of two readings recorded this

  • FEV1

    no effect, p = 0.18

    although the difference between blinded and unblinded studies was not significant (p=0.18)

    PMID 29391776 · one of two readings recorded this

  • FVC

    no effect, p = 0.73

    There was no difference in FVC between theophylline and control groups (p=0.73)

    PMID 29391776 · one of two readings recorded this

  • glucosuria/hyperglycemia

    no effect

    was not different from the active controls in terms of the frequency of psychological side effects, headaches, cardiovascular adverse events, tremor, CPK/CK elevation, or glucosuria/hyperglycemia

    PMID 29391776 · one of two readings recorded this

  • headaches

    no effect

    There were no differences in abdominal pain, psychological side effects, headaches, seizures, or tremor

    PMID 29391776 · one of two readings recorded this

  • headaches

    no effect

    was not different from the active controls in terms of the frequency of psychological side effects, headaches, cardiovascular adverse events, tremor, CPK/CK elevation, or glucosuria/hyperglycemia

    PMID 29391776 · one of two readings recorded this

  • heart rate change after intravenous theophylline, beats per minute, in the placebo-controlled trials

    no effect, no significant difference, p=0.79, p = 0.79

    Not recorded as a finding: the placebo-subgroup sentence is agentless and never names theophylline; the resting-heart-rate node also requires a stated rest position and period, which acute-asthma patients do not have

    In the placebo-controlled trials, no significant difference was noted (p=0.79).

    PMID 29391776 · one of two readings recorded this

  • heart rate

    no effect, p = 0.79

    In the placebo-controlled trials, no significant difference was noted (p=0.79)

    PMID 29391776 · one of two readings recorded this

  • heart rate

    decreases, p = 0.01

    In the active control studies, theophylline lowered the heart rate by 5.17 bpm more than active controls, and this difference was significant (p=0.01)

    PMID 29391776 · one of two readings recorded this

  • heart rate

    no effect, p = 0.32

    At longer-term time points (24–36 hours post-infusion), the difference in heart rate between IV theophylline and control treatments was similar (−3.59 bpm), but failed to reach statistical significance (p=0.32)

    PMID 29391776 · one of two readings recorded this

  • heart rate

    decreases, p = 0.02

    In the short-term (30 minutes–3 hours post-infusion), theophylline lowered the heart rate by 4.17 beats per minute (bpm) compared with control therapy, which was significant (p=0.02)

    PMID 29391776 · one of two readings recorded this

  • nausea

    increases

    Compared with placebo, IV theophylline caused more nausea, vomiting, and cardiovascular adverse events (such as palpitations and arrhythmias)

    PMID 29391776 · one of two readings recorded this

  • nausea

    increases

    Compared with active comparators, theophylline again caused more nausea and vomiting

    PMID 29391776 · one of two readings recorded this

  • oxygen saturation

    no effect

    In almost every case, there were no significant differences between theophylline and control

    PMID 29391776 · one of two readings recorded this

  • PEFR as percent of predicted

    no effect, p = 0.44

    neither the short-term studies (30 minutes–2 hours; p=0.56) nor the longer-term studies (5 hours–48 hours; p=0.44) showed any significant differences between theophylline and control groups

    PMID 29391776 · one of two readings recorded this

  • PEFR as percent of predicted

    no effect, p = 0.56

    neither the short-term studies (30 minutes–2 hours; p=0.56) nor the longer-term studies (5 hours–48 hours; p=0.44) showed any significant differences between theophylline and control groups

    PMID 29391776 · one of two readings recorded this

  • PEFR (L)

    no effect

    There were no significant differences between theophylline and control at either time point

    PMID 29391776 · one of two readings recorded this

  • PEFR (L)

    no effect

    There were no significant differences between theophylline and control at either time point

    PMID 29391776 · one of two readings recorded this

  • psychological side effects

    no effect

    There were no differences in abdominal pain, psychological side effects, headaches, seizures, or tremor

    PMID 29391776 · one of two readings recorded this

  • psychological side effects

    no effect

    was not different from the active controls in terms of the frequency of psychological side effects, headaches, cardiovascular adverse events, tremor, CPK/CK elevation, or glucosuria/hyperglycemia

    PMID 29391776 · one of two readings recorded this

  • respiratory rate

    no effect, p = 0.08

    Theophylline was slightly less effective at lower respiratory rate, although this was not significant (p=0.08)

    PMID 29391776 · one of two readings recorded this

  • seizures

    no effect

    There were no differences in abdominal pain, psychological side effects, headaches, seizures, or tremor

    PMID 29391776 · one of two readings recorded this

  • symptom scores

    no effect

    In almost every case, there were no significant differences between theophylline and control

    PMID 29391776 · one of two readings recorded this

  • symptom scores

    no effect, p = 0.38

    We found that there was no significant difference between adults and children in terms of symptoms (p=0.38)

    PMID 29391776 · one of two readings recorded this

  • tremor

    no effect

    There were no differences in abdominal pain, psychological side effects, headaches, seizures, or tremor

    PMID 29391776 · one of two readings recorded this

  • tremor

    no effect

    was not different from the active controls in terms of the frequency of psychological side effects, headaches, cardiovascular adverse events, tremor, CPK/CK elevation, or glucosuria/hyperglycemia

    PMID 29391776 · one of two readings recorded this

  • use of rescue medication

    no effect

    In almost every case, there were no significant differences between theophylline and control

    PMID 29391776 · one of two readings recorded this

  • vomiting

    increases

    Compared with placebo, IV theophylline caused more nausea, vomiting, and cardiovascular adverse events (such as palpitations and arrhythmias)

    PMID 29391776 · one of two readings recorded this

  • vomiting

    increases

    Compared with active comparators, theophylline again caused more nausea and vomiting

    PMID 29391776 · one of two readings recorded this

  • BSCC breathing component score

    decreases, p = 0.0001

    Breathing | 1.93 (0.83) | 1.41 (0.77) | 1.93 (0.77) | 1.67 (0.78) | −0.279 (–0.381, –0.177) | <0.0001

    PMID 31240995 · one of two readings recorded this

  • BSCC cough component score

    decreases, p = 0.0002

    Cough | 1.71 (0.84) | 1.25 (0.71) | 1.65 (0.86) | 1.41 (0.75) | −0.193 (–0.294, –0.092) | 0.0002

    PMID 31240995 · one of two readings recorded this

  • BSCC sputum component score

    decreases, p = 0.0001

    Sputum | 1.51 (0.84) | 1.14 (0.72) | 1.38 (0.83) | 1.27 (0.75) | −0.208 (–0.308, –0.108) | 0.0001

    PMID 31240995 · one of two readings recorded this

  • COPD exacerbation rate per patient

    decreases

    Exacerbation rates were 43.5% lower in the BUD/FORM plus I + T group (rate 0.069 per patient per 12 weeks; 95% CI: 0.044, 0.106) than the I + T group (rate 0.121

    PMID 31240995 · one of two readings recorded this

  • COPD exacerbation rate ratio

    decreases, p = 0.0425

    of 0.565 (95% CI: 0.325, 0.981; p = 0.0425)

    PMID 31240995 · one of two readings recorded this

  • daytime reliever medication use, last week on treatment

    decreases, p = 0.0102

    mean of last week on treatment 0.97 vs 1.21, respectively; between-treatment difference −0.297 (95% CI: −0.522, −0.071); p = 0.0102

    PMID 31240995 · one of two readings recorded this

  • discontinuation rate

    decreases

    (10.6% versus 5.5%)

    PMID 31240995 · one of two readings recorded this

  • night-time reliever medication use, between-group difference

    no effect, p = 0.2281

    However, the between group difference was not statistically significant [–0.055 (95% CI −0.144, 0.035); p = 0.2281]

    PMID 31240995 · one of two readings recorded this

  • night-time reliever medication use

    decreases

    from a mean of 0.34 doses per night at baseline to 0.26 doses per night during the last week of treatment in the BUD/FORM plus I + T group

    PMID 31240995 · one of two readings recorded this

  • night-time reliever medication use

    decreases

    from 0.31 doses per night to 0.30 doses per night in the I + T group

    PMID 31240995 · one of two readings recorded this

  • postdose FEV1 (5 min), change from baseline to treatment period

    increases, p = 0.0001

    Postdose FEV1 (5 min) (l) a, d | 0.90 | 0.89 | 1.06 | 0.98 | 6.7% | 1.067 | 1.044, 1.090 | <0.0001

    PMID 31240995 · one of two readings recorded this

  • postdose FEV1 (60 min), change from baseline to treatment period

    increases, p = 0.0001

    Postdose FEV1 (60 min) (l) a, d | 0.90 | 0.89 | 1.09 | 1.01 | 6.8% | 1.068 | 1.043, 1.092 | <0.0001

    PMID 31240995 · one of two readings recorded this

  • postdose FVC (5 min), change from baseline to treatment period

    increases, p = 0.0001

    Postdose FVC (5 min) (l) a, d | 2.06 | 2.04 | 2.38 | 2.26 | 4.5% | 1.045 | 1.024, 1.065 | <0.0001

    PMID 31240995 · one of two readings recorded this

  • postdose FVC (60 min), change from baseline to treatment period

    increases, p = 0.0003

    Postdose FVC (60 min) (l) a, d | 2.06 | 2.04 | 2.42 | 2.32 | 3.8% | 1.038 | 1.017, 1.060 | 0.0003

    PMID 31240995 · one of two readings recorded this

  • postdose IC (60 min), change from baseline to treatment period

    increases, p = 0.0074

    Postdose IC (60 min) (l) a, d | 1.70 | 1.70 | 1.97 | 1.89 | 3.8% | 1.038 | 1.010, 1.067 | 0.0074

    PMID 31240995 · one of two readings recorded this

  • postdose morning PEF (5 min), change from baseline to treatment period

    increases, p = 0.0001

    Postdose morning PEF (5 min) (l/min) b | 159 | 160 | 190 | 164 | 27 | NR | 18.906, 35.431 | <0.0001

    PMID 31240995 · one of two readings recorded this

  • predose FEV1, change from baseline to treatment period

    increases, p = 0.0001

    Predose FEV1 (l) a, c | 0.90 | 0.89 | 0.97 | 0.91 | 6.9% | 1.069 | 1.043, 1.096 | <0.0001

    PMID 31240995 · one of two readings recorded this

  • predose FEV1, percent increase from baseline at end of study

    increases

    increased from baseline by 7.9% in the BUD/FORM plus I + T group compared with 0.9% in the I + T group

    PMID 31240995 · one of two readings recorded this

  • predose FVC, change from baseline to treatment period

    increases, p = 0.0007

    Predose FVC (l) a, c | 2.06 | 2.04 | 2.19 | 2.10 | 4.0% | 1.040 | 1.017, 1.064 | <0.0007

    PMID 31240995 · one of two readings recorded this

  • predose IC, change from baseline to treatment period

    increases, p = 0.0248

    Predose IC (l) a, c | 1.70 | 1.70 | 1.82 | 1.75 | 3.5% | 1.035 | 1.004, 1.066 | 0.0248

    PMID 31240995 · one of two readings recorded this

  • predose morning PEF, change from baseline to treatment period

    increases, p = 0.0001

    Predose morning PEF (l/min) b, e | 159 | 160 | 185 | 162 | 23 | NR | 14.927, 31.161 | <0.0001

    PMID 31240995 · one of two readings recorded this

  • SGRQ-C clinically significant improvement (reduction of 4 units or more)

    increases, p = 0.002

    In the BUD/FORM plus I + T group, 62.5% of patients experienced a clinically significant improvement in SGRQ-C score (reduction of ⩾4 units) compared with 49.7% of the I + T group (p = 0.002)

    PMID 31240995 · one of two readings recorded this

  • SGRQ-C total score at baseline

    The mean (SD) SGRQ-C total score at baseline was 67.12 (17.22) in the BUD/FORM

    PMID 31240995 · one of two readings recorded this

  • SGRQ-C total score at baseline

    plus I + T group and 65.18 (16.89) in the I + T group

    PMID 31240995 · one of two readings recorded this

  • SGRQ-C total score improvement from baseline to study end

    decreases, p = 0.0001

    group compared with I + T alone (p < 0.0001)

    PMID 31240995 · one of two readings recorded this

  • time to discontinuation

    increases, p = 0.015

    shorter time to discontinuation (p = 0.015)

    PMID 31240995 · one of two readings recorded this

  • time to first COPD exacerbation

    unclear

    events) for BUD/FORM plus I + T versus I + T was 0.604 (95% CI: 0.339, 1.078;

    PMID 31240995 · one of two readings recorded this

  • breathlessness

    no effect

    Low-dose theophylline had no significant effects on lung function (i.e. FEV1), incidence of pneumonia, mortality, breathlessness or measures of quality of life or disease impact

    PMID 31343402 · one of two readings recorded this

  • hospital admissions due to COPD exacerbation

    decreases, adjusted IRR 0.72, 95% CI 0.55 to 0.94

    Not recorded as a finding: no outcome node for COPD exacerbation hospital admission

    Hospital admissions due to COPD exacerbation were less frequent with low-dose theophylline (adjusted IRR 0.72, 95% CI 0.55 to 0.94).

    PMID 31343402 · both readings recorded this

  • hospital admissions due to COPD exacerbation

    decreases

    Hospital admissions due to COPD exacerbation were less frequent with low-dose theophylline (adjusted IRR 0.72, 95% CI 0.55 to 0.94)

    PMID 31343402 · one of two readings recorded this

  • incidence of pneumonia

    no effect

    Low-dose theophylline had no significant effects on lung function (i.e. FEV1), incidence of pneumonia, mortality, breathlessness or measures of quality of life or disease impact

    PMID 31343402 · one of two readings recorded this

  • lung function (FEV1)

    no effect

    Low-dose theophylline had no significant effects on lung function (i.e. FEV1), incidence of pneumonia, mortality, breathlessness or measures of quality of life or disease impact

    PMID 31343402 · one of two readings recorded this

  • measures of quality of life or disease impact

    no effect

    Low-dose theophylline had no significant effects on lung function (i.e. FEV1), incidence of pneumonia, mortality, breathlessness or measures of quality of life or disease impact

    PMID 31343402 · one of two readings recorded this

  • mortality, 1-year follow-up, cause not stated

    no effect

    Not recorded as a finding: The all-cause-mortality node needs the horizon and a death-from-any-cause definition; the abstract states neither and the null sits inside a multi-endpoint sentence.

    Low-dose theophylline had no significant effects on lung function (i.e. FEV1), incidence of pneumonia, mortality, breathlessness or measures of quality of life or disease impact.

    PMID 31343402 · one of two readings recorded this

  • mortality, horizon not stated in the abstract (lumped into one sentence with lung function, pneumonia, breathlessness and quality of life)

    no effect

    Not recorded as a finding: all-cause-mortality node requires the follow-up horizon and the abstract does not say the deaths are all-cause; abstract-only paper, extracted conservatively

    Low-dose theophylline had no significant effects on lung function (i.e. FEV1), incidence of pneumonia, mortality, breathlessness or measures of quality of life or disease impact.

    PMID 31343402 · one of two readings recorded this

  • mortality

    no effect

    Low-dose theophylline had no significant effects on lung function (i.e. FEV1), incidence of pneumonia, mortality, breathlessness or measures of quality of life or disease impact

    PMID 31343402 · one of two readings recorded this

  • number of participant-reported exacerbations treated with antibiotics and/or oral corticosteroids

    no effect

    The mean number of exacerbations was 2.24 (SD 1.99) for participants allocated to theophylline and 2.23 (SD 1.97) for participants allocated to placebo [adjusted incidence rate ratio (IRR) 0.99, 95% confidence interval (CI) 0.91 to 1.08]

    PMID 31343402 · one of two readings recorded this

  • participant-reported COPD exacerbations treated with antibiotics and/or oral corticosteroids, per person-year

    no effect, adjusted IRR 0.99, 95% CI 0.91 to 1.08

    Not recorded as a finding: no outcome node for COPD exacerbation rate (primary outcome); the abstract sentence naming theophylline is not a single-sentence whole-study quote

    The mean number of exacerbations was 2.24 (SD 1.99) for participants allocated to theophylline and 2.23 (SD 1.97) for participants allocated to placebo [adjusted incidence rate ratio (IRR) 0.99, 95% confidence interval (CI) 0.91 to 1.08].

    PMID 31343402 · one of two readings recorded this

  • participants who ceased trial medication

    no effect

    A higher than expected percentage of participants (26%) ceased trial medication

    PMID 31343402 · one of two readings recorded this

  • reporting of theophylline side effects

    no effect

    There were no differences in the reporting of theophylline side effects between the theophylline and placebo arms

    PMID 31343402 · one of two readings recorded this

  • COPD exacerbation frequency, pooled hazard ratio

    no effect, HR 1.08, 95% CI 0.97 to 1.19, I2 = 95.2%

    Not recorded as a finding: no outcome node for COPD exacerbation rate

    The meta-analysis result demonstrated that theophylline as an add-on therapy to ICS was not associated with the reduction of COPD exacerbation (HR: 1.08, 95%CI: 0.97 to 1.19, I 2 = 95.2%, Fig 2).

    PMID 34029327 · one of two readings recorded this

  • COPD exacerbation (HR)

    no effect

    The meta-analysis result demonstrated that theophylline as an add-on therapy to ICS was not associated with the reduction of COPD exacerbation (HR: 1.08, 95%CI: 0.97 to 1.19, I 2 = 95.2%, Fig 2)

    PMID 34029327 · one of two readings recorded this

  • COPD exacerbation (HR)

    increases

    the result demonstrated that high-dose theophylline led to a significant increase in COPD exacerbation

    PMID 34029327 · one of two readings recorded this

  • COPD exacerbation (HR)

    no effect

    RCTs and cohort studies both indicated that adding theophylline to ICS did not reduce COPD exacerbation

    PMID 34029327 · one of two readings recorded this

  • COPD exacerbation (HR)

    no effect

    RCTs and cohort studies both indicated that adding theophylline to ICS did not reduce COPD exacerbation

    PMID 34029327 · one of two readings recorded this

  • COPD hospitalisation rate, pooled hazard ratio

    increases, HR 1.12, 95% CI 1.10 to 1.15, I2 = 20.4%

    Not recorded as a finding: no outcome node for COPD hospitalisation rate

    In this meta-analysis, the theophylline group demonstrated a higher hospitalization rate compared with the non-theophylline group (HR: 1.12, 95%CI: 1.10 to 1.15, I 2 = 20.4%, Fig 4).

    PMID 34029327 · one of two readings recorded this

  • FEV1

    increases

    This study demonstrated that the theophylline group showed significant improvement in FEV1

    PMID 34029327 · one of two readings recorded this

  • HDAC activity

    no effect

    a double-blind RCT by Cosio et al. reported that the HDAC activity and inflammatory biomarkers were not different in both groups either at baseline or at the end of the study

    PMID 34029327 · one of two readings recorded this

  • HDAC activity

    increases

    The results described that the theophylline arm was associated with a statistically significant increase in HDAC activity and a further reduction in TNF-⍺ and IL-8 concentrations in the sputum compared with the non-theophylline arm

    PMID 34029327 · one of two readings recorded this

  • hospitalization rate (HR)

    increases

    the theophylline group demonstrated a higher hospitalization rate compared with the non-theophylline group (HR: 1.12, 95%CI: 1.10 to 1.15, I 2 = 20.4%, Fig 4)

    PMID 34029327 · one of two readings recorded this

  • IL-8 concentration

    decreases

    The results described that the theophylline arm was associated with a statistically significant increase in HDAC activity and a further reduction in TNF-⍺ and IL-8 concentrations in the sputum compared with the non-theophylline arm

    PMID 34029327 · one of two readings recorded this

  • inflammatory biomarkers

    no effect

    a double-blind RCT by Cosio et al. reported that the HDAC activity and inflammatory biomarkers were not different in both groups either at baseline or at the end of the study

    PMID 34029327 · one of two readings recorded this

  • mortality (HR)

    increases

    the theophylline group was associated with an increased mortality of COPD patients compared with the non-theophylline group (HR: 1.19, 95%CI: 1.14 to 1.25, I 2 = 0%, Fig 5)

    PMID 34029327 · one of two readings recorded this

  • mortality of COPD patients, pooled hazard ratio, theophylline plus ICS versus ICS without theophylline

    increases, HR 1.19 (95%CI 1.14 to 1.25)

    Not recorded as a finding: the paper never states the instrument the node requires

    Similarly, the theophylline group was associated with an increased mortality of COPD patients compared with the non-theophylline group (HR: 1.19, 95%CI: 1.14 to 1.25, I 2 = 0%, Fig 5).

    PMID 34029327 · one of two readings recorded this

  • publication bias (Egger's test)

    no effect, p = 0.419

    these results did not show any evidence of obvious bias (Egger’s test, P = 0.419, S4 Fig)

    PMID 34029327 · one of two readings recorded this

  • TNF-⍺ concentration

    decreases

    The results described that the theophylline arm was associated with a statistically significant increase in HDAC activity and a further reduction in TNF-⍺ and IL-8 concentrations in the sputum compared with the non-theophylline arm

    PMID 34029327 · one of two readings recorded this

  • ADC at 3 h follow-up

    no effect, p = 0.34

    ADC—(SD), mm2/s | 650 (109) | 610 (115) | 0.34a | 770 (72) | 740 (75) | 0.31a | 798 (29) | 803 (34) | 0.88a

    PMID 34259904 · one of two readings recorded this

  • ADC at 3 h follow-up

    no effect, p = 0.31

    ADC—(SD), mm2/s | 650 (109) | 610 (115) | 0.34a | 770 (72) | 740 (75) | 0.31a | 798 (29) | 803 (34) | 0.88a

    PMID 34259904 · one of two readings recorded this

  • ADC at 3 h follow-up

    no effect, p = 0.88

    ADC—(SD), mm2/s | 650 (109) | 610 (115) | 0.34a | 770 (72) | 740 (75) | 0.31a | 798 (29) | 803 (34) | 0.88a

    PMID 34259904 · one of two readings recorded this

  • ADC at baseline

    no effect, p = 0.66

    ADC—(SD), mm2/s | 449 (24) | 450 (27) | 0.66a | 823 (179) | 762 (62) | 0.66a | 826 (46) | 843 (84) | 0.71a

    PMID 34259904 · one of two readings recorded this

  • ADC at baseline

    no effect, p = 0.66

    ADC—(SD), mm2/s | 449 (24) | 450 (27) | 0.66a | 823 (179) | 762 (62) | 0.66a | 826 (46) | 843 (84) | 0.71a

    PMID 34259904 · one of two readings recorded this

  • ADC at baseline

    no effect, p = 0.71

    ADC—(SD), mm2/s | 449 (24) | 450 (27) | 0.66a | 823 (179) | 762 (62) | 0.66a | 826 (46) | 843 (84) | 0.71a

    PMID 34259904 · one of two readings recorded this

  • ADC change from baseline to 3 h

    no effect, p = 0.35

    ADC—(SD), mm2/s | 201 (101) | 159 (110) | 0.35a | −53 (195) | −22 (29) | 0.61a | −29 (54) | −40 (78) | 0.67a

    PMID 34259904 · one of two readings recorded this

  • ADC change from baseline to 3 h

    no effect, p = 0.61

    ADC—(SD), mm2/s | 201 (101) | 159 (110) | 0.35a | −53 (195) | −22 (29) | 0.61a | −29 (54) | −40 (78) | 0.67a

    PMID 34259904 · one of two readings recorded this

  • ADC change from baseline to 3 h

    no effect, p = 0.67

    ADC—(SD), mm2/s | 201 (101) | 159 (110) | 0.35a | −53 (195) | −22 (29) | 0.61a | −29 (54) | −40 (78) | 0.67a

    PMID 34259904 · one of two readings recorded this

  • change in heart rate from baseline to 3-h follow-up, beats per minute

    increases, mean increase 11 bpm (SD 26) versus mean decrease 9 bpm (SD 14), p < 0.05, n = 24

    Not recorded as a finding: resting-heart-rate node requires seated or supine measurement after a stated rest period; the paper states neither position nor rest period for this acute-stroke measurement

    The change in heart rate from baseline to 3‑h follow-up was significantly different (p < 0.05) in the theophylline group (mean increase by 11 beats per minute, SD 26) compared to the control group (mean decrease by 9 beats per minute, SD 14).

    PMID 34259904 · one of two readings recorded this

  • clinical improvement at 3 h follow-up (NIHSS improvement of 4 points or more)

    no effect, p = 1

    Clinical improvement at 3‑h follow-up was present in 1 (8%) patient in the theophylline group and 2 patients (18%) in the control group (p = 1.0)

    PMID 34259904 · one of two readings recorded this

  • diastolic blood pressure change from baseline to 3 h follow-up

    no effect, p = 0.51

    The change in systolic blood pressure (−12 mm Hg, SD 14 versus −8 mm Hg, SD 25; p = 0.62) and the diastolic blood pressure (−9 mm Hg, SD 8 versus −12 mm Hg, SD 12; p = 0.51) from baseline to 3‑h follow-up was similar in the theophylline group and the control group

    PMID 34259904 · one of two readings recorded this

  • early clinical improvement, NIHSS improvement of 4 points or more from baseline to 3 h, proportion of patients

    no effect, 1 (8%) versus 2 (18%), p = 1.0, p = 1, n = 24

    Not recorded as a finding: nih-stroke-scale node is the total score; this is a dichotomised improvement responder proportion

    Clinical improvement at 3‑h follow-up was present in 1 (8%) patient in the theophylline group and 2 patients (18%) in the control group (p = 1.0).

    PMID 34259904 · one of two readings recorded this

  • heart rate change from baseline to 3 h follow-up

    increases, p = 0.05

    The change in heart rate from baseline to 3‑h follow-up was significantly different (p < 0.05) in the theophylline group (mean increase by 11 beats per minute, SD 26) compared to the control group (mean decrease by 9 beats per minute, SD 14)

    PMID 34259904 · one of two readings recorded this

  • NIHSS score at 24 h

    Mean NIHSS score at 24 h (SD) | 7 (6) | 5 (5)

    PMID 34259904 · one of two readings recorded this

  • rCBF at 3 h follow-up

    no effect, p = 0.28

    rCBF—(SD) | 0.88 (0.23) | 0.78 (0.34) | 0.28a | 0.82 (0.17) | 0.80 (0.21) | 0.66a | 0.99 (0.05) | 0.98 (0.04) | 0.47a

    PMID 34259904 · one of two readings recorded this

  • rCBF at 3 h follow-up

    no effect, p = 0.66

    rCBF—(SD) | 0.88 (0.23) | 0.78 (0.34) | 0.28a | 0.82 (0.17) | 0.80 (0.21) | 0.66a | 0.99 (0.05) | 0.98 (0.04) | 0.47a

    PMID 34259904 · one of two readings recorded this

  • rCBF at 3 h follow-up

    no effect, p = 0.47

    rCBF—(SD) | 0.88 (0.23) | 0.78 (0.34) | 0.28a | 0.82 (0.17) | 0.80 (0.21) | 0.66a | 0.99 (0.05) | 0.98 (0.04) | 0.47a

    PMID 34259904 · one of two readings recorded this

  • rCBF at baseline

    no effect, p = 0.16

    rCBF—(SD) | 0.67 (0.28) | 0.50 (0.13) | 0.16a | 0.70 (0.21) | 0.63 (0.17) | 0.51a | 1.01 (0.07) | 1.02 (0.04) | 0.14a

    PMID 34259904 · one of two readings recorded this

  • rCBF at baseline

    no effect, p = 0.51

    rCBF—(SD) | 0.67 (0.28) | 0.50 (0.13) | 0.16a | 0.70 (0.21) | 0.63 (0.17) | 0.51a | 1.01 (0.07) | 1.02 (0.04) | 0.14a

    PMID 34259904 · one of two readings recorded this

  • rCBF at baseline

    no effect, p = 0.14

    rCBF—(SD) | 0.67 (0.28) | 0.50 (0.13) | 0.16a | 0.70 (0.21) | 0.63 (0.17) | 0.51a | 1.01 (0.07) | 1.02 (0.04) | 0.14a

    PMID 34259904 · one of two readings recorded this

  • rCBF change from baseline to 3 h

    no effect, p = 0.65

    rCBF—(SD) | 0.21 (0.33) | 0.27 (0.36) | 0.65b | 0.11 (0.21) | 0.17 (0.16) | 0.51b | −0.02 (0.05) | −0.04 (0.04) | 0.20b

    PMID 34259904 · one of two readings recorded this

  • rCBF change from baseline to 3 h

    no effect, p = 0.51

    rCBF—(SD) | 0.21 (0.33) | 0.27 (0.36) | 0.65b | 0.11 (0.21) | 0.17 (0.16) | 0.51b | −0.02 (0.05) | −0.04 (0.04) | 0.20b

    PMID 34259904 · one of two readings recorded this

  • rCBF change from baseline to 3 h

    no effect, p = 0.2

    rCBF—(SD) | 0.21 (0.33) | 0.27 (0.36) | 0.65b | 0.11 (0.21) | 0.17 (0.16) | 0.51b | −0.02 (0.05) | −0.04 (0.04) | 0.20b

    PMID 34259904 · one of two readings recorded this

  • rCBV at 3 h follow-up

    increases, p = 0.01

    rCBV—(SD) | 0.97 (0.29) | 0.73 (0.15) | 0.01a | 0.97 (0.23) | 0.93 (0.38) | 0.66a | 1.03 (0.09) | 0.99 (0.07) | 0.34a

    PMID 34259904 · one of two readings recorded this

  • rCBV at 3 h follow-up

    no effect, p = 0.66

    rCBV—(SD) | 0.97 (0.29) | 0.73 (0.15) | 0.01a | 0.97 (0.23) | 0.93 (0.38) | 0.66a | 1.03 (0.09) | 0.99 (0.07) | 0.34a

    PMID 34259904 · one of two readings recorded this

  • rCBV at 3 h follow-up

    no effect, p = 0.34

    rCBV—(SD) | 0.97 (0.29) | 0.73 (0.15) | 0.01a | 0.97 (0.23) | 0.93 (0.38) | 0.66a | 1.03 (0.09) | 0.99 (0.07) | 0.34a

    PMID 34259904 · one of two readings recorded this

  • rCBV at baseline

    no effect, p = 0.34

    rCBV—(SD) | 0.93 (0.27) | 0.86 (0.22) | 0.34a | 1.14 (0.31) | 1.01 (0.31) | 0.28a | 1.06 (0.09) | 1.07 (0.09) | 0.75a

    PMID 34259904 · one of two readings recorded this

  • rCBV at baseline

    no effect, p = 0.28

    rCBV—(SD) | 0.93 (0.27) | 0.86 (0.22) | 0.34a | 1.14 (0.31) | 1.01 (0.31) | 0.28a | 1.06 (0.09) | 1.07 (0.09) | 0.75a

    PMID 34259904 · one of two readings recorded this

  • rCBV at baseline

    no effect, p = 0.75

    rCBV—(SD) | 0.93 (0.27) | 0.86 (0.22) | 0.34a | 1.14 (0.31) | 1.01 (0.31) | 0.28a | 1.06 (0.09) | 1.07 (0.09) | 0.75a

    PMID 34259904 · one of two readings recorded this

  • rCBV change from baseline to 3 h

    increases, p = 0.04

    rCBV—(SD) | 0.05 (0.18) | −0.14 (0.24) | 0.04b | −0.17 (0.25) | −0.08 (0.20) | 0.32b | −0.04 (0.07) | −0.08 (0.07) | 0.18b

    PMID 34259904 · one of two readings recorded this

  • rCBV change from baseline to 3 h

    no effect, p = 0.32

    rCBV—(SD) | 0.05 (0.18) | −0.14 (0.24) | 0.04b | −0.17 (0.25) | −0.08 (0.20) | 0.32b | −0.04 (0.07) | −0.08 (0.07) | 0.18b

    PMID 34259904 · one of two readings recorded this

  • rCBV change from baseline to 3 h

    no effect, p = 0.18

    rCBV—(SD) | 0.05 (0.18) | −0.14 (0.24) | 0.04b | −0.17 (0.25) | −0.08 (0.20) | 0.32b | −0.04 (0.07) | −0.08 (0.07) | 0.18b

    PMID 34259904 · one of two readings recorded this

  • recanalization in patients with large vessel occlusion

    no effect, p = 0.11

    Recanalization was found in 7 of 7 patients with LVO in the theophylline group and in 2 of 4 in the control group (p = 0.11)

    PMID 34259904 · one of two readings recorded this

  • recanalization (TIMI 2-3) at 3 h

    Recanalization (TIMI 2–3) at 3 h—no. (%)a | 3 (43) | 3 (75)

    PMID 34259904 · one of two readings recorded this

  • relative cerebral blood volume (rCBV) in the infarct core, change from baseline to 3-h follow-up, perfusion-weighted MRI, theophylline versus placebo as add-on to thrombolysis

    mean change 0.05 (SD 0.18) theophylline versus -0.14 (SD 0.24) control

    Not recorded as a finding: this platform holds no node for the endpoint

    Likewise, there was a statistically significant difference (p < 0.04) regarding the mean rCBV change from baseline to 3‑h follow-up in the theophylline group (mean = 0.05; SD = 0.18) compared to the control group (mean = −0.14; SD = 0.24; Table 2).

    PMID 34259904 · one of two readings recorded this

  • relative cerebral blood volume (rCBV) in the infarct core, perfusion-weighted MRI, change from baseline to 3 h

    increases, mean 0.05 (SD 0.18) versus -0.14 (SD 0.24), p < 0.04, n = 24

    Not recorded as a finding: no outcome node for MRI perfusion parameters (rCBF, rCBV, rMTT)

    Likewise, there was a statistically significant difference (p < 0.04) regarding the mean rCBV change from baseline to 3‑h follow-up in the theophylline group (mean = 0.05; SD = 0.18) compared to the control group (mean = −0.14; SD = 0.24; Table 2).

    PMID 34259904 · one of two readings recorded this

  • rMTT at 3 h follow-up

    no effect, p = 0.34

    rMTT—(SD), sec | 1.87 (2.17) | 1.18 (2.53) | 0.34a | 2.22 (1.85) | 2.34 (1.95) | 0.88a | 0.34 (0.36) | 0.12 (0.29) | 0.11a

    PMID 34259904 · one of two readings recorded this

  • rMTT at 3 h follow-up

    no effect, p = 0.88

    rMTT—(SD), sec | 1.87 (2.17) | 1.18 (2.53) | 0.34a | 2.22 (1.85) | 2.34 (1.95) | 0.88a | 0.34 (0.36) | 0.12 (0.29) | 0.11a

    PMID 34259904 · one of two readings recorded this

  • rMTT at 3 h follow-up

    no effect, p = 0.11

    rMTT—(SD), sec | 1.87 (2.17) | 1.18 (2.53) | 0.34a | 2.22 (1.85) | 2.34 (1.95) | 0.88a | 0.34 (0.36) | 0.12 (0.29) | 0.11a

    PMID 34259904 · one of two readings recorded this

  • rMTT at baseline

    no effect, p = 0.21

    rMTT—(SD), sec | 4.7 (3.6) | 6.5 (3.8) | 0.21a | 6.02 (3.17) | 5.68 (3.17) | 0.93a | 0.34 (0.64) | 0.35 (0.60) | 0.58a

    PMID 34259904 · one of two readings recorded this

  • rMTT at baseline

    no effect, p = 0.93

    rMTT—(SD), sec | 4.7 (3.6) | 6.5 (3.8) | 0.21a | 6.02 (3.17) | 5.68 (3.17) | 0.93a | 0.34 (0.64) | 0.35 (0.60) | 0.58a

    PMID 34259904 · one of two readings recorded this

  • rMTT at baseline

    no effect, p = 0.58

    rMTT—(SD), sec | 4.7 (3.6) | 6.5 (3.8) | 0.21a | 6.02 (3.17) | 5.68 (3.17) | 0.93a | 0.34 (0.64) | 0.35 (0.60) | 0.58a

    PMID 34259904 · one of two readings recorded this

  • rMTT change from baseline to 3 h

    no effect, p = 0.17

    rMTT—(SD), sec | −2.82 (4.26) | −5.32 (4.43) | 0.17b | −3.80 (4.17) | −3.35 (3.16) | 0.77b | −0.00 (0.64) | −0.22 (0.54) | 0.39b

    PMID 34259904 · one of two readings recorded this

  • rMTT change from baseline to 3 h

    no effect, p = 0.77

    rMTT—(SD), sec | −2.82 (4.26) | −5.32 (4.43) | 0.17b | −3.80 (4.17) | −3.35 (3.16) | 0.77b | −0.00 (0.64) | −0.22 (0.54) | 0.39b

    PMID 34259904 · one of two readings recorded this

  • rMTT change from baseline to 3 h

    no effect, p = 0.39

    rMTT—(SD), sec | −2.82 (4.26) | −5.32 (4.43) | 0.17b | −3.80 (4.17) | −3.35 (3.16) | 0.77b | −0.00 (0.64) | −0.22 (0.54) | 0.39b

    PMID 34259904 · one of two readings recorded this

  • systolic blood pressure change from baseline to 3 h follow-up

    no effect, p = 0.62

    The change in systolic blood pressure (−12 mm Hg, SD 14 versus −8 mm Hg, SD 25; p = 0.62) and the diastolic blood pressure (−9 mm Hg, SD 8 versus −12 mm Hg, SD 12; p = 0.51) from baseline to 3‑h follow-up was similar in the theophylline group and the control group

    PMID 34259904 · one of two readings recorded this

  • volume of final FLAIR lesion at 24 h

    Mean volume of final FLAIR lesion at 24 h—ml (SD) | 24.8 (24.8) | 14.7 (14.9)

    PMID 34259904 · one of two readings recorded this

  • adverse events reported

    no effect

    Similarly, there were no reported adverse events

    PMID 34894449 · one of two readings recorded this

  • Global Rating of Smell Change, patient-reported, proportion of responders (slightly, somewhat or much better)

    unclear, difference 3.3%, 95% CI -35.6% to 42.3%, n = 22

    Not recorded as a finding: cgi-improvement-score node is the clinician's CGI-I rating; this is a patient-reported transitional item formatted on the CGI-Change scale and analysed as a responder proportion; no node for the responder proportion

    For the primary outcome measure, slightly more patients in the theophylline group (33%, 4/12) reported improved smell compared to the placebo group (30%, 3/10) (difference 3.3%, 95% CI −35.6% to 42.3%).

    PMID 34894449 · one of two readings recorded this

The whole record — 243 rows